EMJ GOLD
@emjgold.bsky.social
The latest pharma news, views and analysis.
Sign up to our mailing list to receive insights direct to your inbox: https://emjreviews.com/mailing-list/
Sign up to our mailing list to receive insights direct to your inbox: https://emjreviews.com/mailing-list/
Did you know? Patient participation in industry-sponsored trials has fallen by 25% between 2022/23 and 2024/25.
The ABPI argues that this decline is “selling patients short” by reducing opportunities to try new medicines.
Read now: www.emjreviews.com/emj-gold/new...
The ABPI argues that this decline is “selling patients short” by reducing opportunities to try new medicines.
Read now: www.emjreviews.com/emj-gold/new...
December 4, 2025 at 8:45 AM
Did you know? Patient participation in industry-sponsored trials has fallen by 25% between 2022/23 and 2024/25.
The ABPI argues that this decline is “selling patients short” by reducing opportunities to try new medicines.
Read now: www.emjreviews.com/emj-gold/new...
The ABPI argues that this decline is “selling patients short” by reducing opportunities to try new medicines.
Read now: www.emjreviews.com/emj-gold/new...
A new study by Vaccines Europe suggests that the continent's R&D landscape is gathering pace, with 91 vaccine and monoclonal antibody candidates currently in clinical development.
Notably, 41% target pathogens with no existing approved vaccines.
🔗: www.emjreviews.com/emj-gold/new...
Notably, 41% target pathogens with no existing approved vaccines.
🔗: www.emjreviews.com/emj-gold/new...
December 2, 2025 at 8:56 AM
A new study by Vaccines Europe suggests that the continent's R&D landscape is gathering pace, with 91 vaccine and monoclonal antibody candidates currently in clinical development.
Notably, 41% target pathogens with no existing approved vaccines.
🔗: www.emjreviews.com/emj-gold/new...
Notably, 41% target pathogens with no existing approved vaccines.
🔗: www.emjreviews.com/emj-gold/new...
A new AI-driven earpiece could warn people with epilepsy minutes before a seizure, but how? Neuraxpharm and mjnneuro's device monitors brain activity in real time and alerts users via a connected app.
Discover more: www.emjreviews.com/emj-gold/new...
Discover more: www.emjreviews.com/emj-gold/new...
November 28, 2025 at 10:14 AM
A new AI-driven earpiece could warn people with epilepsy minutes before a seizure, but how? Neuraxpharm and mjnneuro's device monitors brain activity in real time and alerts users via a connected app.
Discover more: www.emjreviews.com/emj-gold/new...
Discover more: www.emjreviews.com/emj-gold/new...
From bustling trial centres in Barcelona to a thriving export engine, Spain is a major player in life sciences.
In this piece, find out where its leading the way and where it still has work to do, with insights from Novo Nordisk and Angelini Pharma.
🔗 www.emjreviews.com/emj-gold/art...
In this piece, find out where its leading the way and where it still has work to do, with insights from Novo Nordisk and Angelini Pharma.
🔗 www.emjreviews.com/emj-gold/art...
November 27, 2025 at 3:14 PM
From bustling trial centres in Barcelona to a thriving export engine, Spain is a major player in life sciences.
In this piece, find out where its leading the way and where it still has work to do, with insights from Novo Nordisk and Angelini Pharma.
🔗 www.emjreviews.com/emj-gold/art...
In this piece, find out where its leading the way and where it still has work to do, with insights from Novo Nordisk and Angelini Pharma.
🔗 www.emjreviews.com/emj-gold/art...
Did you know? Scotland generates 20% of the UK's clinical trial revenue.
Now, the country has announced a major new plan to grow its life sciences sector to a £25bn turnover by 2035, aiming to significantly boost healthcare innovation.
Read full story: www.emjreviews.com/emj-gold/new...
Now, the country has announced a major new plan to grow its life sciences sector to a £25bn turnover by 2035, aiming to significantly boost healthcare innovation.
Read full story: www.emjreviews.com/emj-gold/new...
November 21, 2025 at 2:51 PM
Did you know? Scotland generates 20% of the UK's clinical trial revenue.
Now, the country has announced a major new plan to grow its life sciences sector to a £25bn turnover by 2035, aiming to significantly boost healthcare innovation.
Read full story: www.emjreviews.com/emj-gold/new...
Now, the country has announced a major new plan to grow its life sciences sector to a £25bn turnover by 2035, aiming to significantly boost healthcare innovation.
Read full story: www.emjreviews.com/emj-gold/new...
“There comes a day when cancer knocks on your own door.”
In our latest Catalyst interview, hear from AstraZeneca's Dr Vikram Chand, as he reveals how a family experience with cancer altered his views on clinical trial design and much more.
Watch now: www.emjreviews.com/emj-gold/art...
In our latest Catalyst interview, hear from AstraZeneca's Dr Vikram Chand, as he reveals how a family experience with cancer altered his views on clinical trial design and much more.
Watch now: www.emjreviews.com/emj-gold/art...
November 19, 2025 at 4:03 PM
“There comes a day when cancer knocks on your own door.”
In our latest Catalyst interview, hear from AstraZeneca's Dr Vikram Chand, as he reveals how a family experience with cancer altered his views on clinical trial design and much more.
Watch now: www.emjreviews.com/emj-gold/art...
In our latest Catalyst interview, hear from AstraZeneca's Dr Vikram Chand, as he reveals how a family experience with cancer altered his views on clinical trial design and much more.
Watch now: www.emjreviews.com/emj-gold/art...
What is it like to live with chronic lymphocytic leukaemia?
AbbVie's new documentary offers a window into the lives of three patients living with the disease.
Read more: www.emjreviews.com/emj-gold/new...
AbbVie's new documentary offers a window into the lives of three patients living with the disease.
Read more: www.emjreviews.com/emj-gold/new...
November 17, 2025 at 5:07 PM
What is it like to live with chronic lymphocytic leukaemia?
AbbVie's new documentary offers a window into the lives of three patients living with the disease.
Read more: www.emjreviews.com/emj-gold/new...
AbbVie's new documentary offers a window into the lives of three patients living with the disease.
Read more: www.emjreviews.com/emj-gold/new...
Orion Corporation has won Finland's Presidential prize for its global growth.
It won the award for its responsible business practices and role in bringing Finnish medical innovation to the world stage.
Learn more: www.emjreviews.com/emj-gold/new...
It won the award for its responsible business practices and role in bringing Finnish medical innovation to the world stage.
Learn more: www.emjreviews.com/emj-gold/new...
November 14, 2025 at 5:16 PM
Orion Corporation has won Finland's Presidential prize for its global growth.
It won the award for its responsible business practices and role in bringing Finnish medical innovation to the world stage.
Learn more: www.emjreviews.com/emj-gold/new...
It won the award for its responsible business practices and role in bringing Finnish medical innovation to the world stage.
Learn more: www.emjreviews.com/emj-gold/new...
In the latest podcast episode, Giuseppe Savoja, Senior Business Director, Cardiac Surgery in Western Europe at Medtronic, breaks down:
• Today’s ICU challenges
• How ECMO has evolved
• Why industry–clinician collaboration matters
Watch now: www.emjreviews.com/emj-gold/pod...
• Today’s ICU challenges
• How ECMO has evolved
• Why industry–clinician collaboration matters
Watch now: www.emjreviews.com/emj-gold/pod...
November 14, 2025 at 11:59 AM
In the latest podcast episode, Giuseppe Savoja, Senior Business Director, Cardiac Surgery in Western Europe at Medtronic, breaks down:
• Today’s ICU challenges
• How ECMO has evolved
• Why industry–clinician collaboration matters
Watch now: www.emjreviews.com/emj-gold/pod...
• Today’s ICU challenges
• How ECMO has evolved
• Why industry–clinician collaboration matters
Watch now: www.emjreviews.com/emj-gold/pod...
Check out our latest '5 minutes with...' interview featuring Benedikt von Thüngen, Founder and CEO, Sanome, as he explains 'the why' behind his business, its biggest challenge to date and what pharma needs to know about AI.
Read now: www.emjreviews.com/emj-gold/art...
Read now: www.emjreviews.com/emj-gold/art...
November 12, 2025 at 2:16 PM
Check out our latest '5 minutes with...' interview featuring Benedikt von Thüngen, Founder and CEO, Sanome, as he explains 'the why' behind his business, its biggest challenge to date and what pharma needs to know about AI.
Read now: www.emjreviews.com/emj-gold/art...
Read now: www.emjreviews.com/emj-gold/art...
Did you know? Only 51% of low- and middle-income countries can access a life-extending advanced breast cancer treatment.
Our review of VML Health's report explores this issue and insights into research, outcomes and care over the past decade.
Read now: www.emjreviews.com/emj-gold/new...
Our review of VML Health's report explores this issue and insights into research, outcomes and care over the past decade.
Read now: www.emjreviews.com/emj-gold/new...
November 11, 2025 at 2:12 PM
Did you know? Only 51% of low- and middle-income countries can access a life-extending advanced breast cancer treatment.
Our review of VML Health's report explores this issue and insights into research, outcomes and care over the past decade.
Read now: www.emjreviews.com/emj-gold/new...
Our review of VML Health's report explores this issue and insights into research, outcomes and care over the past decade.
Read now: www.emjreviews.com/emj-gold/new...
What is a next-gen patient case study?
In our latest feature, we look at interactive case studies to find out what they can do, how they work and why they meet the needs of time starved healthcare professionals.
Read now: www.emjreviews.com/emj-gold/art...
In our latest feature, we look at interactive case studies to find out what they can do, how they work and why they meet the needs of time starved healthcare professionals.
Read now: www.emjreviews.com/emj-gold/art...
November 6, 2025 at 3:47 PM
What is a next-gen patient case study?
In our latest feature, we look at interactive case studies to find out what they can do, how they work and why they meet the needs of time starved healthcare professionals.
Read now: www.emjreviews.com/emj-gold/art...
In our latest feature, we look at interactive case studies to find out what they can do, how they work and why they meet the needs of time starved healthcare professionals.
Read now: www.emjreviews.com/emj-gold/art...
"Cut VPAG in half tomorrow, and lower corporation tax to compete with Europe the day after"
Discover what bold steps are needed to make the UK a destination of choice for pharma once more, with insight from two experts in the industry.
Read the roundtable: www.emjreviews.com/emj-gold/art...
Discover what bold steps are needed to make the UK a destination of choice for pharma once more, with insight from two experts in the industry.
Read the roundtable: www.emjreviews.com/emj-gold/art...
October 23, 2025 at 10:25 AM
"Cut VPAG in half tomorrow, and lower corporation tax to compete with Europe the day after"
Discover what bold steps are needed to make the UK a destination of choice for pharma once more, with insight from two experts in the industry.
Read the roundtable: www.emjreviews.com/emj-gold/art...
Discover what bold steps are needed to make the UK a destination of choice for pharma once more, with insight from two experts in the industry.
Read the roundtable: www.emjreviews.com/emj-gold/art...
"It’s not just about removing inflammation, but for people to accept, like and feel comfortable in their skin again"
This #WorldMentalHealthDay, Dr Volker Koscielny, Almirall, explores the need to better address the mental health burden of skin conditions hubs.ly/Q03N3VZB0
This #WorldMentalHealthDay, Dr Volker Koscielny, Almirall, explores the need to better address the mental health burden of skin conditions hubs.ly/Q03N3VZB0
October 10, 2025 at 9:47 AM
"It’s not just about removing inflammation, but for people to accept, like and feel comfortable in their skin again"
This #WorldMentalHealthDay, Dr Volker Koscielny, Almirall, explores the need to better address the mental health burden of skin conditions hubs.ly/Q03N3VZB0
This #WorldMentalHealthDay, Dr Volker Koscielny, Almirall, explores the need to better address the mental health burden of skin conditions hubs.ly/Q03N3VZB0
Pharma headlines only tell part of the story.
Our brand-new monthly roundup goes further, sharing the context and analysis behind the biggest news. In this edition, learn about AI’s hidden risks and the off-label trends behind the GLP-1 boom.
Read now: www.emjreviews.com/emj-gold/new...
Our brand-new monthly roundup goes further, sharing the context and analysis behind the biggest news. In this edition, learn about AI’s hidden risks and the off-label trends behind the GLP-1 boom.
Read now: www.emjreviews.com/emj-gold/new...
October 2, 2025 at 8:25 AM
Pharma headlines only tell part of the story.
Our brand-new monthly roundup goes further, sharing the context and analysis behind the biggest news. In this edition, learn about AI’s hidden risks and the off-label trends behind the GLP-1 boom.
Read now: www.emjreviews.com/emj-gold/new...
Our brand-new monthly roundup goes further, sharing the context and analysis behind the biggest news. In this edition, learn about AI’s hidden risks and the off-label trends behind the GLP-1 boom.
Read now: www.emjreviews.com/emj-gold/new...
Social media: What does pharma need to know in 2025?
Discover key trends, challenges and opportunities, with some surprises in store, in our latest article.
Check it out now: www.emjreviews.com/emj-gold/art...
Discover key trends, challenges and opportunities, with some surprises in store, in our latest article.
Check it out now: www.emjreviews.com/emj-gold/art...
September 25, 2025 at 10:49 AM
Social media: What does pharma need to know in 2025?
Discover key trends, challenges and opportunities, with some surprises in store, in our latest article.
Check it out now: www.emjreviews.com/emj-gold/art...
Discover key trends, challenges and opportunities, with some surprises in store, in our latest article.
Check it out now: www.emjreviews.com/emj-gold/art...
Germany was once the “pharmacy of the world”.
Today, its strengths in research, investment and patient access give it a chance to reclaim that crown. But with hurdles in financing, regulation and digital adoption, the question is: can it lead the pack once more?
www.emjreviews.com/emj-gold/art...
Today, its strengths in research, investment and patient access give it a chance to reclaim that crown. But with hurdles in financing, regulation and digital adoption, the question is: can it lead the pack once more?
www.emjreviews.com/emj-gold/art...
September 17, 2025 at 2:05 PM
Germany was once the “pharmacy of the world”.
Today, its strengths in research, investment and patient access give it a chance to reclaim that crown. But with hurdles in financing, regulation and digital adoption, the question is: can it lead the pack once more?
www.emjreviews.com/emj-gold/art...
Today, its strengths in research, investment and patient access give it a chance to reclaim that crown. But with hurdles in financing, regulation and digital adoption, the question is: can it lead the pack once more?
www.emjreviews.com/emj-gold/art...
Pharma is taking psychedelics seriously. AbbVie has just made a billion-dollar bet on a next-generation therapy for depression. See why they invested in this candidate from Gilgamesh Pharmaceuticals👉 www.emjreviews.com/emj-gold/new...
August 26, 2025 at 3:00 PM
Pharma is taking psychedelics seriously. AbbVie has just made a billion-dollar bet on a next-generation therapy for depression. See why they invested in this candidate from Gilgamesh Pharmaceuticals👉 www.emjreviews.com/emj-gold/new...
A new roundtable is live – and this one’s for the pharma marketers.
We spoke to leaders from across the industry to uncover what’s cutting it with today’s HCPs. Unsurprisingly, there are shared challenges, but also plenty of potential solutions.
Read now: hubs.la/Q03DNkV40
We spoke to leaders from across the industry to uncover what’s cutting it with today’s HCPs. Unsurprisingly, there are shared challenges, but also plenty of potential solutions.
Read now: hubs.la/Q03DNkV40
August 21, 2025 at 9:52 AM
A new roundtable is live – and this one’s for the pharma marketers.
We spoke to leaders from across the industry to uncover what’s cutting it with today’s HCPs. Unsurprisingly, there are shared challenges, but also plenty of potential solutions.
Read now: hubs.la/Q03DNkV40
We spoke to leaders from across the industry to uncover what’s cutting it with today’s HCPs. Unsurprisingly, there are shared challenges, but also plenty of potential solutions.
Read now: hubs.la/Q03DNkV40
What’s changing – and what lies ahead – for medical affairs in 2025?
In this episode, Isabel and Jade unpack what HCPs really want, share strategic insights from recent contributors and explore the future of the field – including the role of AI: hubs.la/Q03vqPbT0
#MedicalAffairs #Pharma #Health
In this episode, Isabel and Jade unpack what HCPs really want, share strategic insights from recent contributors and explore the future of the field – including the role of AI: hubs.la/Q03vqPbT0
#MedicalAffairs #Pharma #Health
July 1, 2025 at 2:39 PM
What’s changing – and what lies ahead – for medical affairs in 2025?
In this episode, Isabel and Jade unpack what HCPs really want, share strategic insights from recent contributors and explore the future of the field – including the role of AI: hubs.la/Q03vqPbT0
#MedicalAffairs #Pharma #Health
In this episode, Isabel and Jade unpack what HCPs really want, share strategic insights from recent contributors and explore the future of the field – including the role of AI: hubs.la/Q03vqPbT0
#MedicalAffairs #Pharma #Health
Tune in to the latest episode of the #EMJGOLDPodcast as Richard Maughan, Head of UK Policy and Public Affairs, Pfizer, explores both the promise and the pressures facing the UK healthcare system.
Watch now: www.emjreviews.com/emj-gold/pod...
Watch now: www.emjreviews.com/emj-gold/pod...
June 24, 2025 at 10:00 AM
Tune in to the latest episode of the #EMJGOLDPodcast as Richard Maughan, Head of UK Policy and Public Affairs, Pfizer, explores both the promise and the pressures facing the UK healthcare system.
Watch now: www.emjreviews.com/emj-gold/pod...
Watch now: www.emjreviews.com/emj-gold/pod...
What's ahead for the next decade of hematology care?
This #NationalBloodWeek, Anita Gandhi, VP, Translational Development, BMS, discusses her path into pharma, unmet needs of patients with blood cancer and technologies that are changing the field.
www.emjreviews.com/emj-gold/pod...
This #NationalBloodWeek, Anita Gandhi, VP, Translational Development, BMS, discusses her path into pharma, unmet needs of patients with blood cancer and technologies that are changing the field.
www.emjreviews.com/emj-gold/pod...
June 18, 2025 at 7:44 AM
What's ahead for the next decade of hematology care?
This #NationalBloodWeek, Anita Gandhi, VP, Translational Development, BMS, discusses her path into pharma, unmet needs of patients with blood cancer and technologies that are changing the field.
www.emjreviews.com/emj-gold/pod...
This #NationalBloodWeek, Anita Gandhi, VP, Translational Development, BMS, discusses her path into pharma, unmet needs of patients with blood cancer and technologies that are changing the field.
www.emjreviews.com/emj-gold/pod...
Ready for a fresh perspective on omnichannel engagement?
Tune in to the latest episode of the EMJ GOLD podcast, where Yacin Marzouki shares his expertise on creating meaningful and measurable customer communications.
Watch the episode: www.emjreviews.com/emj-gold/pod...
Tune in to the latest episode of the EMJ GOLD podcast, where Yacin Marzouki shares his expertise on creating meaningful and measurable customer communications.
Watch the episode: www.emjreviews.com/emj-gold/pod...
June 10, 2025 at 3:07 PM
Ready for a fresh perspective on omnichannel engagement?
Tune in to the latest episode of the EMJ GOLD podcast, where Yacin Marzouki shares his expertise on creating meaningful and measurable customer communications.
Watch the episode: www.emjreviews.com/emj-gold/pod...
Tune in to the latest episode of the EMJ GOLD podcast, where Yacin Marzouki shares his expertise on creating meaningful and measurable customer communications.
Watch the episode: www.emjreviews.com/emj-gold/pod...
What hit the headlines in pharma this month?
From new industry appointments to the latest research investments, May brought a wide range of news to the pharmaceutical landscape.
Discover them here: www.emjreviews.com/emj-gold/new...
From new industry appointments to the latest research investments, May brought a wide range of news to the pharmaceutical landscape.
Discover them here: www.emjreviews.com/emj-gold/new...
May 28, 2025 at 2:48 PM
What hit the headlines in pharma this month?
From new industry appointments to the latest research investments, May brought a wide range of news to the pharmaceutical landscape.
Discover them here: www.emjreviews.com/emj-gold/new...
From new industry appointments to the latest research investments, May brought a wide range of news to the pharmaceutical landscape.
Discover them here: www.emjreviews.com/emj-gold/new...
With HCPs more time-starved and digitally fatigued than ever, medical affairs leaders are under pressure to engage with more relevance, brevity and clinical impact.
In our new roundtable, four leaders share what’s working – and what’s not – in 2025.
🔗 www.emjreviews.com/emj-gold/art...
In our new roundtable, four leaders share what’s working – and what’s not – in 2025.
🔗 www.emjreviews.com/emj-gold/art...
May 22, 2025 at 10:46 AM
With HCPs more time-starved and digitally fatigued than ever, medical affairs leaders are under pressure to engage with more relevance, brevity and clinical impact.
In our new roundtable, four leaders share what’s working – and what’s not – in 2025.
🔗 www.emjreviews.com/emj-gold/art...
In our new roundtable, four leaders share what’s working – and what’s not – in 2025.
🔗 www.emjreviews.com/emj-gold/art...